Apoptotic Activity and bcl-2 Immunoreactivity in Meningiomas
Open Access
- 1 July 2000
- journal article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 114 (1) , 84-92
- https://doi.org/10.1309/ulmt-v1uc-d69h-mmqf
Abstract
We retrospectively evaluated 90 meningiomas for bcl-2 expression, apoptosis counts (per 10 high-power fields [HPF]), MIB-1 labeling indices (LI), andKeywords
This publication has 32 references indexed in Scilit:
- Apoptotic BodiesThe American Journal of Surgical Pathology, 1998
- Proliferation and Dna fragmentation in meningioma subtypesNeuropathology and Applied Neurobiology, 1997
- Nuclear and cytoplasmic bcl‐2 expression in endometrial hyperplasia and adenocarcinomaThe Journal of Pathology, 1995
- Expression of bcl‐2 oncoprotein in renal cell tumoursThe Journal of Pathology, 1995
- Apoptosis in cerebral astrocytic tumours and its relationship to expression of the bcl‐2 and p53 proteinsNeuropathology and Applied Neurobiology, 1995
- Atypical and malignant meningiomas: importance of micronecrosis as a prognostic indicatorHistopathology, 1993
- bcl-2 Protein in Non-Small-Cell Lung CarcinomaNew England Journal of Medicine, 1993
- The New WHO Classification of Brain TumoursBrain Pathology, 1993
- Seemingly complete removal of histologically benign intracranial meningioma: Late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysisSurgical Neurology, 1986
- Atypical and anaplastic meningiomas: Radiology, surgery, radiotherapy, and outcomeSurgical Neurology, 1986